| Literature DB >> 28981461 |
Israel Pérez-Torres1, Verónica Guarner-Lans2, María Esther Rubio-Ruiz3.
Abstract
Abstract: Reductive stress (RS) is the counterpart oxidative stress (OS), and can occur in response to conditions that shift the redox balance of important biological redox couples, such as the NAD⁺/NADH, NADP⁺/NADPH, and GSH/GSSG, to a more reducing state. Overexpression of antioxidant enzymatic systems leads to excess reducing equivalents that can deplete reactive oxidative species, driving the cells to RS. A feedback regulation is established in which chronic RS induces OS, which in turn, stimulates again RS. Excess reducing equivalents may regulate cellular signaling pathways, modify transcriptional activity, induce alterations in the formation of disulfide bonds in proteins, reduce mitochondrial function, decrease cellular metabolism, and thus, contribute to the development of some diseases in which NF-κB, a redox-sensitive transcription factor, participates. Here, we described the diseases in which an inflammatory condition is associated to RS, and where delayed folding, disordered transport, failed oxidation, and aggregation are found. Some of these diseases are aggregation protein cardiomyopathy, hypertrophic cardiomyopathy, muscular dystrophy, pulmonary hypertension, rheumatoid arthritis, Alzheimer's disease, and metabolic syndrome, among others. Moreover, chronic consumption of antioxidant supplements, such as vitamins and/or flavonoids, may have pro-oxidant effects that may alter the redox cellular equilibrium and contribute to RS, even diminishing life expectancy.Entities:
Keywords: antioxidants; inflammation; pro-oxidants; reducing equivalents; reductive stress
Mesh:
Substances:
Year: 2017 PMID: 28981461 PMCID: PMC5666780 DOI: 10.3390/ijms18102098
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The redox equilibrium is essential for cellular homeostasis; moderate reactive oxygen species (ROS) production leads to their effects as second messengers. However, ROS overproduction and/or depletion or the antioxidant enzymatic and non-enzymatic systems may lead to oxidative stress. Excess reducing equivalents such as glutathione reduced (GSH)/glutathione oxidized (GSSG) ratio and nicotinamide adenine dinucleotide reduced (NADPH) can depleted all ROS driving to reductive stress by overexpression of antioxidant enzymatic system. Moreover, chronic reductive stress may induce an oxidative stress and stimulated reductive stress by a feedback regulation. Nevertheless, this process it is not yet clearly understood. Adapted from Lubos et al., 2011 [2] and Brewer et al., 2011 [3].
Figure 2Participation of several agents such as the reducing equivalents, antioxidant enzymes and pathologies in reductive stress. Abbreviations: G6PD = glucose 6 phosphate dehydrogenase, NAD = nicotinamide adenine dinucleotide, NAD+ = nicotinamide adenine dinucleotide oxidized, NADH = nicotinamide adenine dinucleotide reduced, NADPH = nicotinamide adenine dinucleotide phosphate reduced, GSH = glutathione, GSSG = glutathione disulfide, PPP = pentose phosphate pathway, γ-glutamyl-cysteine synthase, GSHS = glutathione synthetase, GPx = Glutathione peroxidase, Trx = thioredoxin, Grd = glutaredoxin, TNFα = tumor necrosis factor alpha, NrF2 = erythroid related factor 2, IL6 = interleukin 6, ROS = reactive oxidative species, OS = oxidative stress, ER = endoplasmic reticulum, Se = selenium, Hsp = heat shock protein, GR = glutathione reductase.
Inflammation-associated diseases linked to reductive stress.
| Disease | Source of RS | References |
|---|---|---|
| Cardiomyopathy | ↑ GSH/GSSG ratio | Rajasekaran et al., 2007 [ |
| ↓ Free iron content | Zhang et al., 2010 [ | |
| Pulmonary hypertension | ↑ NADPH/NADP+ ratio | Oldham et al., 2015 [ |
| Stent stenosis | ↑ GSH/GSSG ratio | de Haan., 2014 [ |
| Muscular dystrophy | ↑ GSH/GSSG ratio | Rajasekaran et al., 2007 [ |
| Neurological disorders | ↑ Selenium levels | Tsunoda et al., 2000 [ |
| ↑ GPx activity | Ince et al., 1994 [ | |
| Parkinson’s disease | ↑ NADH/NAD+ ratio | Greenamyre et al., 2010 [ |
| Alzheimer’s disease | ↑ G6PD and GSH | Lloret et al., 2016 [ |
| Metabolic syndrome and insulin resistance | ↑ GPx1 expression | McClung et al., 2004 [ |
| Rheumatoid arthritis | ↑ NADPH/NADP+ ratio | Yang et al., 2016 [ |
| Renal diseases | ↑ GSH/GSSG ratio | Li et al., 1993 [ |
| ↑ Thiols | Welch et al., 1992 [ | |
| Cancer | ↑ NADH/NAD+ ratio | Oldham et al., 2015 [ |
(↓): reduction; (↑): increase. Abbreviations: RS: reductive stress; GSH: glutathione; GSSG: glutathione disulfide; G6PD: glucose-6-phosphate dehydrogenase; NADH: Nicotinamide adenine dinucleotide reduced; NAD+: Nicotinamide adenine dinucleotide oxidized; NADPH: Nicotinamide adenine dinucleotide phosphate reduced; NADP+: Nicotinamide adenine dinucleotide phosphate oxidized; GPx: gluthathione peroxidase 1.
Side effects of antioxidant agents in inflammation-associated diseases.
| Antioxidant Agent | Mechanisms | Associated Pathology | References |
|---|---|---|---|
| Tocopherol or Vitamin E | Pro-oxidant activity by Fenton reaction | Bone alterations | Smith et al., 2005 [ |
| NAC | Reduction of NAD+/NADH ratio | Cardiovascular disorders | Zhang et al., 2012 [ |
| β-carotene | Pro-oxidant and pro-inflammatory | Cancer | Goodman et al., 1996 [ |
| Ascorbic acid (Vitamin C) | Pro-oxidant activity by Fenton reaction | Renal calcium oxalate deposition | Hatch et al., 1980 [ |
| BHA and BHT | Pro-oxidative properties | Cancer | Branen, 1975 [ |
| Flavonoids | Pro-oxidant activity by Fenton reaction | DNA damage, Apoptosis | Hodnick et al., 1986 [ |
| Resveratrol | Pro-oxidant by CYP2C9 | Endothelial cell death | Posadino et al., 2015 [ |
| Coumaric Acid | Pro-oxidant | Endothelial cell death | Posadino et al., 2013 [ |
| Estrogens | Pro-oxidative properties | Cell damage | Ayres et al., 1998 [ |
Abbreviations: NAC: N-acetylcysteine; NADH: Nicotinamide adenine dinucleotide reduced; NAD+: Nicotinamide adenine dinucleotide oxidized; BHA: Hydroxyanisole; BHT: butylated hydroxytoluene.